CECarolin Ertl

Carolin Ertl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carolin Ertl has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cytokine release syndrome across three immunotherapy platforms: A real-world patient-level comparison of CAR T-cell, T-cell engager, and immune checkpoint inhibitor therapies

    by Lisa Wein, Carolin Ertl, Kai Rejeski, Richard David-Rus, Mingzi Kong-Bild, Rebecca Pusl, Lisa Frölich, Dirk Tomsitz, Louisa von Baumgarten, Marion Subklewe, et al.

  • Open Access

    Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study

    by Lisa Wein, Carolin Ertl, Theresa Ruf, Monika Morak, Ying Wang, Christina Schmitt, Xiomara Garza Vazquez, Valerie Glatzel, Richard David-Rus, Mohammed Mitwalli, et al.

    Background: Immune checkpoint inhibitor-induced immune-related adverse events (irAEs) can be steroid-refractory (sr) or steroid-dependent (sd), requiring second-line therapy. Evidence guiding optimal management of sr/sd-irAEs while preserving antitumor efficacy is scarce. This study compared extracorporeal photopheresis (ECP) with systemic immunosuppressants (IS) for treatment of sr/sd-irAEs. Methods: This prospective two-arm study included 46 patients (23 ECP, 23 IS) with 12 distinct types of irAEs across 6 tumor entities, all classified as steroid-refractory or steroid-dependent. Toxicities affected the gastrointestinal tract, skin, lung, musculoskeletal system, and serosal membranes, with up to seven prior irAE treatment lines. Patients received six cycles of ECP or investigator’s choice IS over 12 weeks. Longitudinal assessments included clinical irAE outcomes, quality of life (QoL), and tumor response. ECP was more frequently used in patients with multi-toxicity (39% vs 9%; p=0.02) and multi-resistance to prior second-line immunosuppression (39% vs 17%; p=0.19). Results: At week 12, ECP showed a lower cumulative corticosteroid exposure (395 mg vs 1,260 mg prednisolone equivalent; p=0.03), significantly improved QoL (p=0.01), and a numerically higher irAE response rate without statistical significance compared with IS (94% vs 81%; p=0.85). In advanced cutaneous melanoma, ECP was associated with superior overall survival (15 vs 10 months; p=0.02), and longer progression-free survival (9 vs 3 months; p=0.01). No significant safety concerns were observed with ECP; one fatality in the IS group was infection-related. Conclusions: ECP demonstrated clinical outcomes comparable to IS in sr/sd-irAEs, with significantly lower cumulative corticosteroid exposure and improved QoL. Furthermore, ECP was associated with a favorable safety profile and showed no evidence of compromised antitumor activity. A multicenter trial is planned for further investigation. Trial registration number: NCT05700565 .


  • Open Access

    Real-world management and outcomes of immune-related adverse events in german cancer care: A multicenter analysis using the SERIO registry

    by Carolin Ertl, Dirk Tomsitz, Filippo Rizzo, Dirk Hempel, Lucie Heinzerling, Valeria Milani

    Background: Immune checkpoint inhibitors (ICIs) are widely used in cancer therapy, yet diagnosing and managing immune-related adverse events (irAEs) remains challenging in clinical practice. Differences in healthcare structures between university hospitals (UH) and private practices (PP) influence irAE presentation and management, often excluding the latter from analyses. Patients and Methods: This retrospective study included 604 cancer patients treated with ICIs between 2014 and 2023: 323 from UH and 281 from PP. In total, 302 irAEs were reported in the Side Effect Registry Immuno-Oncology (SERIO; http://www.serio-registry.org), with 230 cases from UH and 72 from PP. Demographics, irAE characteristics, management, and outcomes were compared between settings. Results: The UH and PP cohorts showed substantial differences. IrAEs were less frequent in the PP cohort (19% vs. 51%) and less severe (grade 3/4: 35% PP vs. 40% UH). Time to diagnosis was longer in PP (136 vs. 86 days), but treatment response rates were comparable (90% PP vs. 84% UH). UH patients experienced better symptom control (24% vs. 16%) and fewer long-term sequelae (6% vs. 10%). No irAE-related mortality occurred in either group. Conclusion: Structural differences between UH and PP impact the frequency, severity, and management of irAEs. Including underrepresented care settings in real-world analysis is essential for generating robust, generalizable evidence. By enhancing collaboration between academic institutions and community-based practitioners, we aim to improve irAE outcomes and promote more equitable, evidence-based care in immuno-oncology.